Market closed
ALX Oncology/$ALXO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
$ALXO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
89
Website
ALX Oncology Metrics
BasicAdvanced
$91M
Market cap
-
P/E ratio
-$2.97
EPS
1.04
Beta
-
Dividend rate
Price and volume
Market cap
$91M
Beta
1.04
52-week high
$17.83
52-week low
$1.19
Average daily volume
931K
Financial strength
Current ratio
4.821
Quick ratio
4.631
Long term debt to equity
11.324
Total debt to equity
12.688
Interest coverage (TTM)
-93.11%
Management effectiveness
Return on assets (TTM)
-49.24%
Return on equity (TTM)
-98.94%
Valuation
Price to book
0.66
Price to tangible book (TTM)
0.66
Price to free cash flow (TTM)
-0.673
Growth
Earnings per share change (TTM)
-16.85%
3-year earnings per share growth (CAGR)
16.81%
What the Analysts think about ALX Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.
ALX Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALX Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALX Oncology News
AllArticlesVideos
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
GlobeNewsWire·4 weeks ago
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ALX Oncology stock?
ALX Oncology (ALXO) has a market cap of $91M as of December 11, 2024.
What is the P/E ratio for ALX Oncology stock?
The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of December 11, 2024.
Does ALX Oncology stock pay dividends?
No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next ALX Oncology dividend payment date?
ALX Oncology (ALXO) stock does not pay dividends to its shareholders.
What is the beta indicator for ALX Oncology?
ALX Oncology (ALXO) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.